Levosimendan Waymade (Levosimendan)

Levosimendan works by binding to troponin C, increasing the sensitivity of the contractile apparatus to calcium without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal function. The prescriber sets the loading dose, infusion rate, and duration according to established guidelines and individual needs.

Safety data for levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Levosimendan differs from traditional inotropes such as dobutamine by increasing calcium sensitivity rather than intracellular calcium, which may reduce the risk of arrhythmias. Unlike phosphodiesterase inhibitors like milrinone, it also provides vasodilation through potassium‑channel activation, offering a combined inotropic and vasodilatory effect.

Levosimendan intravenous solution should be stored at 2‑8 °C, protected from light, and must not be frozen. The product should be kept in its original packaging until use and handled with aseptic technique to maintain sterility.

Levosimendan is given as an intravenous infusion. Typically a loading dose is administered over 10 minutes followed by a continuous infusion for up to 24 hours, but the exact regimen is set by the treating physician based on patient condition and response.

Serious risks include severe hypotension, myocardial ischemia, ventricular arrhythmias, and rare allergic reactions. Continuous cardiovascular monitoring is essential during infusion to detect and manage these events promptly.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension, obstructive cardiomyopathy, or uncontrolled ventricular arrhythmias. Caution is also advised in severe renal or hepatic impairment and in patients receiving other potent vasodilators.